Business
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the field
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy","length":135,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immunotherapy for oncology, inflammation, and autoimmunity.","length":428,"tagName":"p"},{"type":"text","content":"By combining academic research with industrial expertise, the partnership seeks to transform cutting-edge immunology discoveries into industrial programs capable of delivering breakthrough therapies to patients. This large-scale public–private alliance strengthens long-standing ties with the Immunotherapy Innovation Hub in Nantes and sets the stage for expanding this collaborative model nationwide in the years ahead.","length":420,"tagName":"p"},{"type":"text","content":"To achieve these objectives, the partners will unite their scientific teams and pool their expertise and know-how to transform innovative projects into programs ready for industrial development. As part of this new partnership, the project identification process led by Inserm Transfert and Nantes University will enable OSE Immunotherapeutics to access the most promising and relevant programs emerging from the research units of Nantes University and Inserm. Selected projects will benefit from financial support and dedicated guidance.","length":538,"tagName":"p"},{"type":"text","content":"Pascale Augé, Chairwoman of the Exe...